This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center.
In an interview, Larry Ereshefsky, PharmD, discussed other conditions brilaroxazine could potentially treat other than schizophrenia due to its mechanism.
The field of cardiac care is constantly evolving, and healthcare professionals must stay at the forefront of advancements to provide the highest quality of treatment to their patients. Recognizing this imperative, ADN CoE recently organized a comprehensive SVT Ablation Training program at the prestigious 9 Eylül University Heart Rhythm Management Centre.
A single-center assessment showed patients with glomerulonephritis may face a heightened risk of primary disease recurrence up to 1 year after transplant.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Publication date: Available online 26 April 2024 Source: The American Journal of Cardiology Author(s): Alberto Cordero, David Sirera, José Méndez-Gallego, Ignacio Echeverría
KDpredict uses age, sex, eGFR, and albuminuria to calculate 1-5 year risk of kidney failure and death in chronic kidney disease, outperforming the kidney failure risk equation.
Publication date: Available online 27 April 2024 Source: The American Journal of Cardiology Author(s): Aditya S. Bharadwaj, Alexander G. Truesdell, Alejandro Lemor, Julia B. Thompson, Arsalan Abu-Much, Yiran Zhang, Michael J. Schonning, David J. Cohen, Alexandra J. Lansky, William W.
Publication date: Available online 27 April 2024 Source: The American Journal of Cardiology Author(s): Aditya S. Bharadwaj, Alexander G. Truesdell, Alejandro Lemor, Julia B. Thompson, Arsalan Abu-Much, Yiran Zhang, Michael J. Schonning, David J. Cohen, Alexandra J. Lansky, William W.
Publication date: Available online 26 April 2024 Source: The American Journal of Cardiology Author(s): Areesha Moiz, Jeremy Y. Levett, Kristian B. Filion, Katya Peri, Pauline Reynier, Mark J.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content